Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Drug

EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review

Fineline Cube Feb 13, 2023

EOC Pharma, a biotech operating out of the US and China, has announced that a...

Company Drug

Joincare’s Generic Seretide Accepted for NMPA Review

Fineline Cube Feb 10, 2023

China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...

Company Deals

Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs

Fineline Cube Feb 10, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...

Company Drug

Everest Medicines’ Nefecon Included in South Korea’s GIFT Program

Fineline Cube Feb 10, 2023

China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug...

Company Deals

Haohai Bio Acquires Additional Stake in SZNIMO for Ophthalmic Expansion

Fineline Cube Feb 10, 2023

China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366), a leading biomaterial firm...

Company Drug

Hinova’s HP530S Accepted for NMPA Review as FAK Inhibitor for Solid Tumors

Fineline Cube Feb 10, 2023

China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its...

Company

AstraZeneca Reports Q4 and Full-Year 2022 Results with Strong Revenue Growth

Fineline Cube Feb 10, 2023

UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4...

Company Drug

Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval

Fineline Cube Feb 9, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...

Company Deals

Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board

Fineline Cube Feb 9, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for...

Company Deals

Shanghai Pinnacles Partners with Sysmex for Biochemical Immune Diagnosis Solutions

Fineline Cube Feb 9, 2023

China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation,...

Company Deals

GenScript ProBio Partners with Bio Immunitas for hRPP Platform

Fineline Cube Feb 9, 2023

Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a...

Company Drug

ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment

Fineline Cube Feb 9, 2023

Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011...

Company Deals

Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs

Fineline Cube Feb 9, 2023

China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...

Company Deals

Neurodawn Completes Series A+ Financing for CNS Drug Development

Fineline Cube Feb 9, 2023

Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has...

Company Drug

Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study

Fineline Cube Feb 9, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...

Company Deals

Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering

Fineline Cube Feb 9, 2023

Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional...

Company Deals

Teddy Clinical Research Lab Partners with Cerba Research for Global Services

Fineline Cube Feb 9, 2023

China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244)...

Company Deals

Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma

Fineline Cube Feb 8, 2023

Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...

Company Deals

Macrolux Secures Series A Funding for Endoscopy Solutions

Fineline Cube Feb 8, 2023

Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB...

Company Deals

Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin

Fineline Cube Feb 8, 2023

China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...

Posts pagination

1 … 577 578 579 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.